Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fennec Pharmaceuticals Inc. FENC
$7.65
-$0.22 (-2.86%)
На 18:00, 12 мая 2023
+102.61%
Потенциал через год
Ранг: 4
Ключевые показатели
-
Marketcap
207120256.00000000
-
week52high
10.85
-
week52low
5.00
-
Revenue
1535000
-
P/E TTM
-6
-
Beta
0.16124500
-
EPS
-0.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 03 июн 2021 г. |
| Craig-Hallum | Buy | 21 апр 2021 г. | |
| Maxim Group | Buy | 19 апр 2021 г. | |
| Cantor Fitzgerald | Overweight | 05 июн 2020 г. | |
| H.C. Wainwright | Buy | 15 мая 2020 г. | |
| Capital One | Overweight | 07 сент 2022 г. | |
| Wedbush | Outperform | Outperform | 26 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 окт 2022 г. |
| Cantor Fitzgerald | Overweight | Neutral | 22 ноя 2022 г. |
| HC Wainwright & Co. | Buy | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Raykov Rosty | D | 217838 | 8400 | 30 дек 2022 г. |
| Raykov Rosty | D | 226238 | 1600 | 30 дек 2022 г. |
| Andrade Robert | D | 149721 | 5500 | 30 дек 2022 г. |
| Raykov Rosty | D | 227838 | 5000 | 29 дек 2022 г. |
| Andrade Robert | D | 155221 | 5500 | 29 дек 2022 г. |
| Raykov Rosty | D | 232838 | 13740 | 28 дек 2022 г. |
| Andrade Robert | D | 160721 | 11000 | 28 дек 2022 г. |
| RALLIS CHRIS A | D | 30018 | 333 | 17 ноя 2022 г. |
| RALLIS CHRIS A | D | 30351 | 2068 | 20 окт 2022 г. |
| RALLIS CHRIS A | A | 32419 | 4762 | 20 окт 2022 г. |
Новостная лента
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 08:24
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.14 per share a year ago.
Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
GlobeNewsWire
08 мая 2023 г. в 06:15
RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Fennec Pharmaceuticals Gains Momentum With Industry Endorsements
Seeking Alpha
05 апр 2023 г. в 08:43
Fennec Pharmaceuticals received FDA approval for Pedmark, a drug addressing cisplatin-induced ototoxicity in pediatric patients. The National Comprehensive Cancer Network (NCCN) and the European Medicines Agency (EMA) have endorsed Pedmark, strengthening its market prospects.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
30 мар 2023 г. в 08:22
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale
Seeking Alpha
16 янв 2023 г. в 05:45
After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark. Additionally, the company secured non-dilutive capital to help initial commercialization efforts. While the market for Pedmark is limited, its critical use in the prevention of cisplatin-related hearing loss in pediatric patients assures market viability.